Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | ACE | P12821 | 8/20 | 0.46 |
| ▸ | REN | P00797 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PEPD | P12955 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9893422 | 0.88 | RAB9A (0.55) | RAB9AHSD17B10LMNACYP2C19SMN1; SMN2 | |
| SCHEMBL12769056 | 0.88 | RAB9A (0.55) | RAB9AHSD17B10LMNACYP2C19SMN1; SMN2 | |
| SCHEMBL27877016 | 0.84 | HSD17B10 (0.69) | RAB9AHSD17B10LMNACYP2C19SMN1; SMN2 | |
| SCHEMBL6219872 | 0.84 | HSD17B10 (0.69) | RAB9AHSD17B10LMNACYP2C19SMN1; SMN2 | |
| SCHEMBL85536 | 0.84 | HSD17B10 (0.69) | RAB9AHSD17B10LMNACYP2C19SMN1; SMN2 | |
| SCHEMBL67045 | 0.84 | HSD17B10 (0.69) | RAB9AHSD17B10LMNACYP2C19SMN1; SMN2 | |
| SCHEMBL67044 | 0.84 | HSD17B10 (0.69) | RAB9AHSD17B10LMNACYP2C19SMN1; SMN2 | |
| SCHEMBL20492528 | 0.83 | HSD17B10 (0.68) | RAB9AHSD17B10LMNACYP2C19SMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL28264574 | 0.83 | HSD17B10 (0.68) | RAB9AHSD17B10LMNACYP2C19SMN1; SMN2 | |
| Hydrazine SCHEMBL28122430 | 0.81 | HSD17B10 (0.66) | RAB9AHSD17B10LMNACYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1973875-B1 | COMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS | INFINITY DISCOVERY INC (US) | 2014-06-11 | — | — | EP | disclosed |
| US-8304428-B2 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | INFINITY DISCOVERY, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-20100190791-A1 | Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners | INFINITY PHARMACEUTICALS, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-7745464-B2 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | INFINITY DISCOVERY, INC. | 2010-06-29 | — | — | US | disclosed |
| EP-1973875-A1 | COMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS | Infinity Discovery, Inc. (US) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007075387-A1 | COMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS | INFINITY DISCOVERY, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070155705-A1 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | INFINITY PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190791-A1 | Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners | BCL3, BCL2, BCL2L1 | RAB9A 2066/4885HSD17B10 2893/4885LMNA 3205/4885 |
| US-20070155705-A1 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | BCL3, BCL2, BCL2L1 | RAB9A 2066/4885HSD17B10 2893/4885LMNA 3205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.